Log in to save to my catalogue

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2277529203

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Selinexor, a drug that inhibits nuclear export of tumor suppressor proteins, was tested in a phase 2 trial involving patients with myeloma whose disease had progressed despite treatment with proteasome inhibitors, immunomodulatory agents, alkylating agents, and monoclonal antibodies. A partial response or better was observed in 26% of patients, and...

Alternative Titles

Full title

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2277529203

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2277529203

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1903455

How to access this item